Clinical Trial Update: A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia [Phase 3]

View source ↗

Summary

A phase 3 long-term study of PA21 in hemodialysis patients with hyperphosphatemia has been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease with Hyperphosphatemia
• Hyperphosphatemia in Patients Undergoing Hemodialysis

Drugs mentioned

• PA21 (PA21)

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Hemodialysis Patients With Hyperphosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2018-10-09